CANCER&RESEARCH&UK&& & - - PowerPoint PPT Presentation

CANCER&RESEARCH&UK&& &

IAN&WALKER&PHD,&MBA& DIRECTOR,&STRATEGIC&PARTNERSHIPS&

An&introduc>on&to&CRUK&

Cancer&Research&UK&

Who&we&are&

– The$largest$fundraising$medical$research$charity$in$the$world.$ – The$largest$funder$of$cancer$research$in$Europe.$ – The$second$largest$$global$funder$of$cancer$research$a9er$the$US$ government.$

What&we&spend&

– We$spent$£338m$on$research$in$2012/13$ – We$are$almost$exclusively$funded$through$public$donaFons$ – The$money$we$raise$is$spent$on$$

• Research$
• InformaFon$
• Advocacy$and$public$policy$

&

A&UKEwide&network&with&unique&capabili>es&

– 5$coreEfunded&ins>tutes& – 15$Cancer&Centres& – 4&Cancer&Imaging&Centres& – 18&ECMCs& – 7&Clinical&Trials&Units& – Our&Drug&Development& Office$

Our&Strategy&

6$

Cancer&Research&UK’s&Ambi>on&

Over the last 40 years, cancer survival in the UK has doubled. In the 1970s just a quarter of people survived. Today that figure is half. Our ambition is to accelerate progress an see three-quarters of patients surviving the disease within the next 20 years.

We&intend&to&achieve&our&ambi>on&through&a&substan>al& increase&in&research&spend&in&the&following&areas&

Early& diagnosis& research$ Basic& understanding&

• f&cancer$

Cancer& preven>on$ Therapeu>c& innova>on$ Precision& medicine$ Cancers of substantial unmet need To help deliver these priorities, we will: Invest in our translational network Encourage collaborative approaches Develop the best researchers Launch new funding schemes

Greater&understanding&of&interEpa>ent&heterogeneity&has& highlighted&its&impact&on&prognosis&&&treatment&response &

Redefining breast cancer: the METABRIC study

Patient outlook

5 8 7 4 3 9 6 1 10*& 2

Extremely poor Good Intermediate Poor Cluster

*Poor 5-year outcome; good long-term outcome if alive at 5 years * EGFRexon 19 deletions or exon 21 (L858R) substitution mutations

Mutational spectrum in Lung Adenocarcinoma

10$disFnct$clusters$with$varying$clinical$

• utcome$

NSCLC&pa>ent&group& PFS&gain&Erlo>nib&vs&chemo&

EGFR$mutant*$ 5.2$mths$ EGFR$WT$ O1.9$mths$

The % distribution of clinically relevant driver mutations identified to date in individuals with lung adenocarcinoma. (TGCA, Nature, 548, vol 511 (2014))

Significant&technology&advances,&have&accelerated&the& progress&in&precision&medicine&

$1k$ $10k$ $100k$ $1,000k$ $10,000k$ $100,000k$ SepO01$ MayO02$ JanO03$ SepO03$ MayO04$ JanO05$ SepO05$ MayO06$ JanO07$ SepO07$ MayO08$ JanO09$ SepO09$ MayO10$ JanO11$ SepO11$ MayO12$ JanO13$ SepO13$

Sanger&sequencing& Next&genera>on&sequencing&

Current cost of NGS whole genome sequencing is c. $4,000

Moore’s law

1: National Human Genome Research Institute, Data from the NHGRI Genome Sequencing Program (GSP) http://www.genome.gov/sequencingcosts/ .

The dramatic decrease in the cost of Whole Genome Sequencing has outpaced Moore’s Law1

Response&to&crizo>nib&in&ALK+&adenocarcinoma&

July 2012 baseline Sept 2012 duration of crizotinib tx: 1 month

Thanks to Dr Sanjay Popat (RMH), for providing this slide

CRUK& STRATIFIED& MEDICINE&&2&

A&collabora>ve&model&

• The programme represents

a combined investment of

• ver £20M by the funding

Partners.

• Up to 14 drugs could be

involved over the course of the programme.

Biomarker etc Drug etc Biomarker A : Drug A Biomarker B : Drug B Biomarker C : Drug C Biomarker D : Drug D Biomarker E: Drug E Biomarker F : Drug F

NGS sequencing

• Upto$2000$NSCLC$paFents$screened$per$year$
• NaFonal$screening$to$naFonal$trial$
• 28$gene$mulFplexed$NGS$panel;$detects$mutaFons,$

deleFons,$CNV$and$DNA$rearrangement$

• UFlising$DNA$from$rouFne$FFPE$biopsies$
• 6$drugs,$14$straFfied$arms$to$begin$with$
• Phase$2a$signal$finding$study$
• Rolling$protocol,$capable$of$incorporaFng$new$arms$
• Sponsored$by$CRCTU$at$Birmingham$
• PI$Professor$Gary$Middleton$
• Recruit$across$18$ECMC$centres$

Pre-screening MATRIX Lung Study

DiagnosFc$ biopsy$ Generic$ consent$ NHS$ Treatment$ Consent$for$ study$$ NHS$Treatment$ Recruit$to$drug$1$ Recruit$to$drug$2$ Recruit$to$drug$3$ Recruit$to$drug$n$

EGFR$ e.g.$BRAF$

Recruit$if$ posiFve$ NHS$single$ gene$test$ Single$gene$ test$for$study$$ e.g.$NGS$ Panel$test$$ If$test$ negaFve$ Collabora've** pre,screening*

SMP2:&An&Alterna>ve&Approach&

• Shared$cost$
• Quicker$
• Easier$for$

paFents$

• Fewer$

rebiopsies$

• Includes$

rare$ mutaFons$

Current*pathway*

– SMP2$will$change$the$way$we$develop$straFfied$medicines$ within$the$UK$and$provide$greater$opFons$for$paFents$with$ lung$cancer.$$ – The$programme$will$be$a$NaFonal$effort$across$the$enFre$ ECMC$network$and$beyond.$ – A$model$uFlising$shared$preOscreening$provides$benefits$for$ paFents,$Sponsors$and$pharmaceuFcal$companies$

Summary&

END& cruk.org&